-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On February 17, CStone announced that the new drug application for pratinib has been accepted in Taiwan, China, the drug is mainly used for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC), advanced or metastatic medullary thyroid gland cancer (MTC) and advanced or metastatic thyroid cancer (TC)
.
In addition, CStone's avatinib tablets were approved for marketing in Taiwan, China in April 2021
.
.
In addition, CStone's avatinib tablets were approved for marketing in Taiwan, China in April 2021
.
$2 billion variety, the first IDH1 inhibitor in China launched
On February 9, CStone's first-of-its-kind drug, ivonib, was approved for marketing in China
.
According to reports, the drug is the first IDH1 inhibitor approved in China for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (R/R AML) who carry IDH1 susceptibility mutations
.
.
According to reports, the drug is the first IDH1 inhibitor approved in China for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (R/R AML) who carry IDH1 susceptibility mutations
.
Avonib is the original research drug of Agios Pharmaceuticals introduced by CStone, and it is also the only approved IDH1 inhibitor in the world
.
On July 20, 2018, ivonib was approved by the U.
S.
Food and Drug Administration (FDA) for the treatment of adults with IDH1-mutated R/R AML
.
In late 2020, Servier acquired Agios' oncology business, which included Avonib, for $2 billion
.
According to the annual financial report of Agios Pharmaceuticals, the global sales of Avonib in 2020 are 2 billion US dollars
.
.
On July 20, 2018, ivonib was approved by the U.
S.
Food and Drug Administration (FDA) for the treatment of adults with IDH1-mutated R/R AML
.
In late 2020, Servier acquired Agios' oncology business, which included Avonib, for $2 billion
.
According to the annual financial report of Agios Pharmaceuticals, the global sales of Avonib in 2020 are 2 billion US dollars
.
In addition to AML, related tumors such as cholangiocarcinoma, chondrosarcoma, and glioma are all associated with IDH1 mutations
.
On August 25, 2021, ivonib was approved by the U.
S.
Food and Drug Administration (FDA) for the treatment of cholangiocarcinoma
.
At present, there are very few companies under development of IDH1 inhibitors in the world.
According to the global new drug research and development data of Minet.
com, there are 6 IDH1 inhibitors in the world, including HMPL-306, ES-481,
etc.
.
On August 25, 2021, ivonib was approved by the U.
S.
Food and Drug Administration (FDA) for the treatment of cholangiocarcinoma
.
At present, there are very few companies under development of IDH1 inhibitors in the world.
According to the global new drug research and development data of Minet.
com, there are 6 IDH1 inhibitors in the world, including HMPL-306, ES-481,
etc.
Global 1DH1 inhibitor research and development status
Focus on innovative drug projects, and launch 4 new drugs in a year
CStone focuses on the FIC/BIC R&D model, and focuses on the "independent R&D + introduction" strategy.
Currently, more than 20 product pipelines of the company are innovative drug projects
.
According to the global new drug R&D data of Minet.
com, CStone Pharmaceuticals has a total of 21 innovative drug products, and 12 products are in the clinical stage and above (the new drugs already on the market and new indications are not included), of which 1 is a new drug product A total of 5 models, including sugelimab that has been marketed in China, CS-1003 that has entered clinical phase III, and CS-3002, CS-3005, CS-3006 that are in clinical phase I, etc.
A total of 6 models
.
Currently, more than 20 product pipelines of the company are innovative drug projects
.
According to the global new drug R&D data of Minet.
com, CStone Pharmaceuticals has a total of 21 innovative drug products, and 12 products are in the clinical stage and above (the new drugs already on the market and new indications are not included), of which 1 is a new drug product A total of 5 models, including sugelimab that has been marketed in China, CS-1003 that has entered clinical phase III, and CS-3002, CS-3005, CS-3006 that are in clinical phase I, etc.
A total of 6 models
.
Up to now, CStone Pharmaceuticals has 4 innovative drugs approved in China.
In addition to avonib and sugelimab, it also includes pratinib and avatinib introduced by Blueprint Medicine .
less than a year apart
.
In addition to avonib and sugelimab, it also includes pratinib and avatinib introduced by Blueprint Medicine .
less than a year apart
.
Avatinib and pratinib were listed earlier in China, and both were approved during March 2021.
Among them, pratinib is the first selective RET inhibitor approved in China.
The commercial profit effect is remarkable
.
According to CStone's financial report, CStone's revenue in the first half of 2021 will reach approximately 79.
4 million yuan, and the revenue of avatinib and pratinib will be approximately 33.
6 million yuan and 45.
8 million yuan, respectively
.
Among them, pratinib is the first selective RET inhibitor approved in China.
The commercial profit effect is remarkable
.
According to CStone's financial report, CStone's revenue in the first half of 2021 will reach approximately 79.
4 million yuan, and the revenue of avatinib and pratinib will be approximately 33.
6 million yuan and 45.
8 million yuan, respectively
.
It is worth noting that CStone's sugelimab, which was approved for marketing at the end of 2021, is also eye-catching
.
Sugalimab is the second domestically-made PD-L1 monoclonal antibody approved in China.
It is used in combination with chemotherapy for stage IV NSCLC patients.
In addition, the new drug marketing application for stage III NSCLC patients is currently under review, and it is expected to become a global drug in the future.
The first immunotherapy drug to cover both stage III and IV non-small cell lung cancer (NSCLC) the whole population, so this drug is regarded as a potential best-in-class PD-L1 antibody in the industry
.
In 2020, CStone ceded the domestic and overseas rights of sugelimab to Pfizer and EQRx
.
EQRx has said that it is estimated that for non-small cell lung cancer alone, the annual sales of sugelimab are expected to reach more than 2 billion US dollars in the short term after the listing
.
.
Sugalimab is the second domestically-made PD-L1 monoclonal antibody approved in China.
It is used in combination with chemotherapy for stage IV NSCLC patients.
In addition, the new drug marketing application for stage III NSCLC patients is currently under review, and it is expected to become a global drug in the future.
The first immunotherapy drug to cover both stage III and IV non-small cell lung cancer (NSCLC) the whole population, so this drug is regarded as a potential best-in-class PD-L1 antibody in the industry
.
In 2020, CStone ceded the domestic and overseas rights of sugelimab to Pfizer and EQRx
.
EQRx has said that it is estimated that for non-small cell lung cancer alone, the annual sales of sugelimab are expected to reach more than 2 billion US dollars in the short term after the listing
.
CStone's product pipeline
Covering the field of high-incidence cancer types, "three antibodies" seize the best in class
In terms of indications, CStone's product pipeline mainly covers anti-tumor therapy, and will focus on subdivided cancer types such as lung cancer, liver cancer, digestive tract cancer, and bile duct cancer, especially lung cancer and other high-incidence cancer types, which occupy the Half of the marketed products (pratinib, sugalimumab), and among the related drug candidates, lorlatinib has recently been approved by the State Food and Drug Administration for clinical trials for this indication, CS-2006, CS-3005 and other non-small cell lung cancer indications are in clinical phase I and preclinical stages
.
Among them, CS-2006 is a trispecific antibody targeting PD-L1, 4-1BB and HSA, which can achieve improved efficacy while reducing toxicity
.
.
Among them, CS-2006 is a trispecific antibody targeting PD-L1, 4-1BB and HSA, which can achieve improved efficacy while reducing toxicity
.
Furthermore, liver cancer has also become the direction that CStone has recently focused on expanding
.
Judging from the pipeline of candidate drugs under development, CS-1003, a class 1 new drug, has the fastest development speed among the candidate drugs, and a global phase III clinical trial of combination therapy with lenvatinib for liver cancer is carried out.
The second is the introduction of a new drug fisotinib (BLU-554), which has entered a phase II clinical trial in combination with CS1001 for liver cancer
.
.
Judging from the pipeline of candidate drugs under development, CS-1003, a class 1 new drug, has the fastest development speed among the candidate drugs, and a global phase III clinical trial of combination therapy with lenvatinib for liver cancer is carried out.
The second is the introduction of a new drug fisotinib (BLU-554), which has entered a phase II clinical trial in combination with CS1001 for liver cancer
.
In addition to anti-tumor therapy, CStone is also involved in the field of anti-gout.
The candidate drug CS3001 is a urate reabsorption transporter (URAT1) inhibitor, which is still in the preclinical stage
.
Among the domestic URAT1 inhibitor similar drug companies , Hengrui has made the fastest progress, and SLC22A12 has entered the clinical phase III; (YL-90148) and other enterprise-related products have entered the phase II clinical stage
.
The candidate drug CS3001 is a urate reabsorption transporter (URAT1) inhibitor, which is still in the preclinical stage
.
Among the domestic URAT1 inhibitor similar drug companies , Hengrui has made the fastest progress, and SLC22A12 has entered the clinical phase III; (YL-90148) and other enterprise-related products have entered the phase II clinical stage
.
In terms of target layout, CStone is one of the few companies in China that also has clinical-stage PD-1, PD-L1 and CTLA-4 immuno- oncology backbone drugs
.
However, in recent years, PD-(L)1 has blossomed everywhere, and the probability of drug resistance or recurrence of the corresponding target antibody treatment regimen has increased
.
In this regard, CStone has used combination therapy for PD-(L)1 drugs such as sugelimab, CS-2006 and CS-1003 to improve the disadvantages of previous monotherapy
.
However, at present, the technical barriers for combination drugs are often high, and it is difficult to advance clinical trials.
If CStone can cover more drug resources that can be used for combination therapy, the company will gain greater market advantages in the future
.
.
However, in recent years, PD-(L)1 has blossomed everywhere, and the probability of drug resistance or recurrence of the corresponding target antibody treatment regimen has increased
.
In this regard, CStone has used combination therapy for PD-(L)1 drugs such as sugelimab, CS-2006 and CS-1003 to improve the disadvantages of previous monotherapy
.
However, at present, the technical barriers for combination drugs are often high, and it is difficult to advance clinical trials.
If CStone can cover more drug resources that can be used for combination therapy, the company will gain greater market advantages in the future
.
Source: Mi intranet database
On February 17, CStone announced that the new drug application for pratinib has been accepted in Taiwan, China, the drug is mainly used for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC), advanced or metastatic medullary thyroid gland cancer (MTC) and advanced or metastatic thyroid cancer (TC)
.
In addition, CStone's avatinib tablets were approved for marketing in Taiwan, China in April 2021
.
.
In addition, CStone's avatinib tablets were approved for marketing in Taiwan, China in April 2021
.
$2 billion variety, the first IDH1 inhibitor in China launched
On February 9, CStone's first-of-its-kind drug, ivonib, was approved for marketing in China
.
According to reports, the drug is the first IDH1 inhibitor approved in China for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (R/R AML) who carry IDH1 susceptibility mutations
.
.
According to reports, the drug is the first IDH1 inhibitor approved in China for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (R/R AML) who carry IDH1 susceptibility mutations
.
Avonib is the original research drug of Agios Pharmaceuticals introduced by CStone, and it is also the only approved IDH1 inhibitor in the world
.
On July 20, 2018, ivonib was approved by the U.
S.
Food and Drug Administration (FDA) for the treatment of adults with IDH1-mutated R/R AML
.
In late 2020, Servier acquired Agios' oncology business, which included Avonib, for $2 billion
.
According to the annual financial report of Agios Pharmaceuticals, the global sales of Avonib in 2020 are 2 billion US dollars
.
.
On July 20, 2018, ivonib was approved by the U.
S.
Food and Drug Administration (FDA) for the treatment of adults with IDH1-mutated R/R AML
.
In late 2020, Servier acquired Agios' oncology business, which included Avonib, for $2 billion
.
According to the annual financial report of Agios Pharmaceuticals, the global sales of Avonib in 2020 are 2 billion US dollars
.
In addition to AML, related tumors such as cholangiocarcinoma, chondrosarcoma, and glioma are all associated with IDH1 mutations
.
On August 25, 2021, ivonib was approved by the U.
S.
Food and Drug Administration (FDA) for the treatment of cholangiocarcinoma
.
At present, there are very few companies under development of IDH1 inhibitors in the world.
According to the global new drug research and development data of Minet.
com, there are 6 IDH1 inhibitors in the world, including HMPL-306, ES-481,
etc.
.
On August 25, 2021, ivonib was approved by the U.
S.
Food and Drug Administration (FDA) for the treatment of cholangiocarcinoma
.
At present, there are very few companies under development of IDH1 inhibitors in the world.
According to the global new drug research and development data of Minet.
com, there are 6 IDH1 inhibitors in the world, including HMPL-306, ES-481,
etc.
Global 1DH1 inhibitor research and development status
Focus on innovative drug projects, and launch 4 new drugs in a year
CStone focuses on the FIC/BIC R&D model, and focuses on the "independent R&D + introduction" strategy.
Currently, more than 20 product pipelines of the company are innovative drug projects
.
According to the global new drug R&D data of Minet.
com, CStone Pharmaceuticals has a total of 21 innovative drug products, and 12 products are in the clinical stage and above (the new drugs already on the market and new indications are not included), of which 1 is a new drug product A total of 5 models, including sugelimab that has been marketed in China, CS-1003 that has entered clinical phase III, and CS-3002, CS-3005, CS-3006 that are in clinical phase I, etc.
A total of 6 models
.
Currently, more than 20 product pipelines of the company are innovative drug projects
.
According to the global new drug R&D data of Minet.
com, CStone Pharmaceuticals has a total of 21 innovative drug products, and 12 products are in the clinical stage and above (the new drugs already on the market and new indications are not included), of which 1 is a new drug product A total of 5 models, including sugelimab that has been marketed in China, CS-1003 that has entered clinical phase III, and CS-3002, CS-3005, CS-3006 that are in clinical phase I, etc.
A total of 6 models
.
Up to now, CStone Pharmaceuticals has 4 innovative drugs approved in China.
In addition to avonib and sugelimab, it also includes pratinib and avatinib introduced by Blueprint Medicine .
less than a year apart
.
In addition to avonib and sugelimab, it also includes pratinib and avatinib introduced by Blueprint Medicine .
less than a year apart
.
Avatinib and pratinib were listed earlier in China, and both were approved during March 2021.
Among them, pratinib is the first selective RET inhibitor approved in China.
The commercial profit effect is remarkable
.
According to CStone's financial report, CStone's revenue in the first half of 2021 will reach approximately 79.
4 million yuan, and the revenue of avatinib and pratinib will be approximately 33.
6 million yuan and 45.
8 million yuan, respectively
.
Among them, pratinib is the first selective RET inhibitor approved in China.
The commercial profit effect is remarkable
.
According to CStone's financial report, CStone's revenue in the first half of 2021 will reach approximately 79.
4 million yuan, and the revenue of avatinib and pratinib will be approximately 33.
6 million yuan and 45.
8 million yuan, respectively
.
It is worth noting that CStone's sugelimab, which was approved for marketing at the end of 2021, is also eye-catching
.
Sugalimab is the second domestically-made PD-L1 monoclonal antibody approved in China.
It is used in combination with chemotherapy for stage IV NSCLC patients.
In addition, the new drug marketing application for stage III NSCLC patients is currently under review, and it is expected to become a global drug in the future.
The first immunotherapy drug to cover both stage III and IV non-small cell lung cancer (NSCLC) the whole population, so this drug is regarded as a potential best-in-class PD-L1 antibody in the industry
.
In 2020, CStone ceded the domestic and overseas rights of sugelimab to Pfizer and EQRx
.
EQRx has said that it is estimated that for non-small cell lung cancer alone, the annual sales of sugelimab are expected to reach more than 2 billion US dollars in the short term after the listing
.
.
Sugalimab is the second domestically-made PD-L1 monoclonal antibody approved in China.
It is used in combination with chemotherapy for stage IV NSCLC patients.
In addition, the new drug marketing application for stage III NSCLC patients is currently under review, and it is expected to become a global drug in the future.
The first immunotherapy drug to cover both stage III and IV non-small cell lung cancer (NSCLC) the whole population, so this drug is regarded as a potential best-in-class PD-L1 antibody in the industry
.
In 2020, CStone ceded the domestic and overseas rights of sugelimab to Pfizer and EQRx
.
EQRx has said that it is estimated that for non-small cell lung cancer alone, the annual sales of sugelimab are expected to reach more than 2 billion US dollars in the short term after the listing
.
CStone's product pipeline
Covering the field of high-incidence cancer types, "three antibodies" seize the best in class
In terms of indications, CStone's product pipeline mainly covers anti-tumor therapy, and will focus on subdivided cancer types such as lung cancer, liver cancer, digestive tract cancer, and bile duct cancer, especially lung cancer and other high-incidence cancer types, which occupy the Half of the marketed products (pratinib, sugalimumab), and among the related drug candidates, lorlatinib has recently been approved by the State Food and Drug Administration for clinical trials for this indication, CS-2006, CS-3005 and other non-small cell lung cancer indications are in clinical phase I and preclinical stages
.
Among them, CS-2006 is a trispecific antibody targeting PD-L1, 4-1BB and HSA, which can achieve improved efficacy while reducing toxicity
.
.
Among them, CS-2006 is a trispecific antibody targeting PD-L1, 4-1BB and HSA, which can achieve improved efficacy while reducing toxicity
.
Furthermore, liver cancer has also become the direction that CStone has recently focused on expanding
.
Judging from the pipeline of candidate drugs under development, CS-1003, a class 1 new drug, has the fastest development speed among the candidate drugs, and a global phase III clinical trial of combination therapy with lenvatinib for liver cancer is carried out.
The second is the introduction of a new drug fisotinib (BLU-554), which has entered a phase II clinical trial in combination with CS1001 for liver cancer
.
.
Judging from the pipeline of candidate drugs under development, CS-1003, a class 1 new drug, has the fastest development speed among the candidate drugs, and a global phase III clinical trial of combination therapy with lenvatinib for liver cancer is carried out.
The second is the introduction of a new drug fisotinib (BLU-554), which has entered a phase II clinical trial in combination with CS1001 for liver cancer
.
In addition to anti-tumor therapy, CStone is also involved in the field of anti-gout.
The candidate drug CS3001 is a urate reabsorption transporter (URAT1) inhibitor, which is still in the preclinical stage
.
Among the domestic URAT1 inhibitor similar drug companies , Hengrui has made the fastest progress, and SLC22A12 has entered the clinical phase III; (YL-90148) and other enterprise-related products have entered the phase II clinical stage
.
The candidate drug CS3001 is a urate reabsorption transporter (URAT1) inhibitor, which is still in the preclinical stage
.
Among the domestic URAT1 inhibitor similar drug companies , Hengrui has made the fastest progress, and SLC22A12 has entered the clinical phase III; (YL-90148) and other enterprise-related products have entered the phase II clinical stage
.
In terms of target layout, CStone is one of the few companies in China that also has clinical-stage PD-1, PD-L1 and CTLA-4 immuno- oncology backbone drugs
.
However, in recent years, PD-(L)1 has blossomed everywhere, and the probability of drug resistance or recurrence of the corresponding target antibody treatment regimen has increased
.
In this regard, CStone has used combination therapy for PD-(L)1 drugs such as sugelimab, CS-2006 and CS-1003 to improve the disadvantages of previous monotherapy
.
However, at present, the technical barriers for combination drugs are often high, and it is difficult to advance clinical trials.
If CStone can cover more drug resources that can be used for combination therapy, the company will gain greater market advantages in the future
.
.
However, in recent years, PD-(L)1 has blossomed everywhere, and the probability of drug resistance or recurrence of the corresponding target antibody treatment regimen has increased
.
In this regard, CStone has used combination therapy for PD-(L)1 drugs such as sugelimab, CS-2006 and CS-1003 to improve the disadvantages of previous monotherapy
.
However, at present, the technical barriers for combination drugs are often high, and it is difficult to advance clinical trials.
If CStone can cover more drug resources that can be used for combination therapy, the company will gain greater market advantages in the future
.
Source: Mi intranet database
On February 17, CStone announced that the new drug application for pratinib has been accepted in Taiwan, China, the drug is mainly used for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC), advanced or metastatic medullary thyroid gland cancer (MTC) and advanced or metastatic thyroid cancer (TC)
.
In addition, CStone's avatinib tablets were approved for marketing in Taiwan, China in April 2021
.
.
In addition, CStone's avatinib tablets were approved for marketing in Taiwan, China in April 2021
.
$2 billion variety, the first IDH1 inhibitor in China launched
$2 billion variety, the first IDH1 inhibitor in China launched On February 9, CStone's first-of-its-kind drug, ivonib, was approved for marketing in China
.
According to reports, the drug is the first IDH1 inhibitor approved in China for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (R/R AML) who carry IDH1 susceptibility mutations
.
.
According to reports, the drug is the first IDH1 inhibitor approved in China for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (R/R AML) who carry IDH1 susceptibility mutations
.
Avonib is the original research drug of Agios Pharmaceuticals introduced by CStone, and it is also the only approved IDH1 inhibitor in the world
.
On July 20, 2018, ivonib was approved by the U.
S.
Food and Drug Administration (FDA) for the treatment of adults with IDH1-mutated R/R AML
.
In late 2020, Servier acquired Agios' oncology business, which included Avonib, for $2 billion
.
According to the annual financial report of Agios Pharmaceuticals, the global sales of Avonib in 2020 are 2 billion US dollars
.
.
On July 20, 2018, ivonib was approved by the U.
S.
Food and Drug Administration (FDA) for the treatment of adults with IDH1-mutated R/R AML
.
In late 2020, Servier acquired Agios' oncology business, which included Avonib, for $2 billion
.
According to the annual financial report of Agios Pharmaceuticals, the global sales of Avonib in 2020 are 2 billion US dollars
.
In addition to AML, related tumors such as cholangiocarcinoma, chondrosarcoma, and glioma are all associated with IDH1 mutations
.
On August 25, 2021, ivonib was approved by the U.
S.
Food and Drug Administration (FDA) for the treatment of cholangiocarcinoma
.
At present, there are very few companies under development of IDH1 inhibitors in the world.
According to the global new drug research and development data of Minet.
com, there are 6 IDH1 inhibitors in the world, including HMPL-306, ES-481,
etc.
.
On August 25, 2021, ivonib was approved by the U.
S.
Food and Drug Administration (FDA) for the treatment of cholangiocarcinoma
.
At present, there are very few companies under development of IDH1 inhibitors in the world.
According to the global new drug research and development data of Minet.
com, there are 6 IDH1 inhibitors in the world, including HMPL-306, ES-481,
etc.
Global 1DH1 inhibitor research and development status
Focus on innovative drug projects, and launch 4 new drugs in a year
Focus on innovative drug projects, and launch 4 new drugs in a year CStone focuses on the FIC/BIC R&D model, and focuses on the "independent R&D + introduction" strategy.
Currently, more than 20 product pipelines of the company are innovative drug projects
.
According to the global new drug R&D data of Minet.
com, CStone Pharmaceuticals has a total of 21 innovative drug products, and 12 products are in the clinical stage and above (the new drugs already on the market and new indications are not included), of which 1 is a new drug product A total of 5 models, including sugelimab that has been marketed in China, CS-1003 that has entered clinical phase III, and CS-3002, CS-3005, CS-3006 that are in clinical phase I, etc.
A total of 6 models
.
Currently, more than 20 product pipelines of the company are innovative drug projects
.
According to the global new drug R&D data of Minet.
com, CStone Pharmaceuticals has a total of 21 innovative drug products, and 12 products are in the clinical stage and above (the new drugs already on the market and new indications are not included), of which 1 is a new drug product A total of 5 models, including sugelimab that has been marketed in China, CS-1003 that has entered clinical phase III, and CS-3002, CS-3005, CS-3006 that are in clinical phase I, etc.
A total of 6 models
.
Up to now, CStone Pharmaceuticals has 4 innovative drugs approved in China.
In addition to avonib and sugelimab, it also includes pratinib and avatinib introduced by Blueprint Medicine .
less than a year apart
.
medicine medicine medicineIn addition to avonib and sugelimab, it also includes pratinib and avatinib introduced by Blueprint Medicine .
less than a year apart
.
Avatinib and pratinib were listed earlier in China, and both were approved during March 2021.
Among them, pratinib is the first selective RET inhibitor approved in China.
The commercial profit effect is remarkable
.
According to CStone's financial report, CStone's revenue in the first half of 2021 will reach approximately 79.
4 million yuan, and the revenue of avatinib and pratinib will be approximately 33.
6 million yuan and 45.
8 million yuan, respectively
.
Among them, pratinib is the first selective RET inhibitor approved in China.
The commercial profit effect is remarkable
.
According to CStone's financial report, CStone's revenue in the first half of 2021 will reach approximately 79.
4 million yuan, and the revenue of avatinib and pratinib will be approximately 33.
6 million yuan and 45.
8 million yuan, respectively
.
It is worth noting that CStone's sugelimab, which was approved for marketing at the end of 2021, is also eye-catching
.
Sugalimab is the second domestically-made PD-L1 monoclonal antibody approved in China.
It is used in combination with chemotherapy for stage IV NSCLC patients.
In addition, the new drug marketing application for stage III NSCLC patients is currently under review, and it is expected to become a global drug in the future.
The first immunotherapy drug to cover both stage III and IV non-small cell lung cancer (NSCLC) the whole population, so this drug is regarded as a potential best-in-class PD-L1 antibody in the industry
.
In 2020, CStone ceded the domestic and overseas rights of sugelimab to Pfizer and EQRx
.
EQRx has said that it is estimated that for non-small cell lung cancer alone, the annual sales of sugelimab are expected to reach more than 2 billion US dollars in the short term after the listing
.
.
Sugalimab is the second domestically-made PD-L1 monoclonal antibody approved in China.
It is used in combination with chemotherapy for stage IV NSCLC patients.
In addition, the new drug marketing application for stage III NSCLC patients is currently under review, and it is expected to become a global drug in the future.
The first immunotherapy drug to cover both stage III and IV non-small cell lung cancer (NSCLC) the whole population, so this drug is regarded as a potential best-in-class PD-L1 antibody in the industry
.
In 2020, CStone ceded the domestic and overseas rights of sugelimab to Pfizer and EQRx
.
EQRx has said that it is estimated that for non-small cell lung cancer alone, the annual sales of sugelimab are expected to reach more than 2 billion US dollars in the short term after the listing
.
CStone's product pipeline
Covering the field of high-incidence cancer types, "three antibodies" seize the best in class
Covering the field of high-incidence cancer types, "three antibodies" seize the best in class In terms of indications, CStone's product pipeline mainly covers anti-tumor therapy, and will focus on subdivided cancer types such as lung cancer, liver cancer, digestive tract cancer, and bile duct cancer, especially lung cancer and other high-incidence cancer types, which occupy the Half of the marketed products (pratinib, sugalimumab), and among the related drug candidates, lorlatinib has recently been approved by the State Food and Drug Administration for clinical trials for this indication, CS-2006, CS-3005 and other non-small cell lung cancer indications are in clinical phase I and preclinical stages
.
Among them, CS-2006 is a trispecific antibody targeting PD-L1, 4-1BB and HSA, which can achieve improved efficacy while reducing toxicity
.
.
Among them, CS-2006 is a trispecific antibody targeting PD-L1, 4-1BB and HSA, which can achieve improved efficacy while reducing toxicity
.
Furthermore, liver cancer has also become the direction that CStone has recently focused on expanding
.
Judging from the pipeline of candidate drugs under development, CS-1003, a class 1 new drug, has the fastest development speed among the candidate drugs, and a global phase III clinical trial of combination therapy with lenvatinib for liver cancer is carried out.
The second is the introduction of a new drug fisotinib (BLU-554), which has entered a phase II clinical trial in combination with CS1001 for liver cancer
.
.
Judging from the pipeline of candidate drugs under development, CS-1003, a class 1 new drug, has the fastest development speed among the candidate drugs, and a global phase III clinical trial of combination therapy with lenvatinib for liver cancer is carried out.
The second is the introduction of a new drug fisotinib (BLU-554), which has entered a phase II clinical trial in combination with CS1001 for liver cancer
.
In addition to anti-tumor therapy, CStone is also involved in the field of anti-gout.
The candidate drug CS3001 is a urate reabsorption transporter (URAT1) inhibitor, which is still in the preclinical stage
.
Among the domestic URAT1 inhibitor similar drug companies , Hengrui has made the fastest progress, and SLC22A12 has entered the clinical phase III; (YL-90148) and other enterprise-related products have entered the phase II clinical stage
.
enterprise enterprise enterpriseThe candidate drug CS3001 is a urate reabsorption transporter (URAT1) inhibitor, which is still in the preclinical stage
.
Among the domestic URAT1 inhibitor similar drug companies , Hengrui has made the fastest progress, and SLC22A12 has entered the clinical phase III; (YL-90148) and other enterprise-related products have entered the phase II clinical stage
.
In terms of target layout, CStone is one of the few companies in China that also has clinical-stage PD-1, PD-L1 and CTLA-4 immuno- oncology backbone drugs
.
However, in recent years, PD-(L)1 has blossomed everywhere, and the probability of drug resistance or recurrence of the corresponding target antibody treatment regimen has increased
.
In this regard, CStone has used combination therapy for PD-(L)1 drugs such as sugelimab, CS-2006 and CS-1003 to improve the disadvantages of previous monotherapy
.
However, at present, the technical barriers for combination drugs are often high, and it is difficult to advance clinical trials.
If CStone can cover more drug resources that can be used for combination therapy, the company will gain greater market advantages in the future
.
tumor tumor tumor.
However, in recent years, PD-(L)1 has blossomed everywhere, and the probability of drug resistance or recurrence of the corresponding target antibody treatment regimen has increased
.
In this regard, CStone has used combination therapy for PD-(L)1 drugs such as sugelimab, CS-2006 and CS-1003 to improve the disadvantages of previous monotherapy
.
However, at present, the technical barriers for combination drugs are often high, and it is difficult to advance clinical trials.
If CStone can cover more drug resources that can be used for combination therapy, the company will gain greater market advantages in the future
.
Source: Mi intranet database
